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182Objective: b-Blockers improve outcomes in patients with heart failure or a history of myocardial infarction, but it
remains uncertain whether they are beneficial after the perioperative period in cardiac surgery patients without
these conditions. This study was designed to examine whether discharge use of b-blockers was associated
with outcomes after hospitalization in patients who had undergone nontransplant cardiac surgery.
Methods:We analyzed outcomes in a prospective cohort of 3102 patients discharged alive after cardiac surgery
(2547 of whom had undergone coronary artery bypass grafting surgery) between September 2002 and August
2005.
Results: b-Blockers were prescribed for 2580 (83%) patients at hospital discharge. Over a mean follow-up of
75 months (standard deviation, 20 months), 10% (259/2580) of patients discharged with b-blockers and 19%
(97/522) not prescribed b-blockers at the time of hospital discharge died (hazard ratio of 0.65 [95% confidence
interval, 0.49–0.87] after adjustment for covariates). One-year mortality was also lower in those discharged with
b-blockers: 2.2% (57/2580) in b-blocker users versus 7.2% (38/522) in nonusers (adjusted odds ratio, 0.54 [95%
confidence interval, 0.30–0.97]). The association between b-blocker use and lower mortality was consistent
across all examined subgroups, including patients without prior myocardial infarction or without heart failure
(all P< .01).
Conclusions: Patients discharged with b-blockers after cardiac surgery exhibit a substantially lower mortality
rate during long-term follow-up, even among those without a history of myocardial infarction or heart failure.
(J Thorac Cardiovasc Surg 2010;140:182-7)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surgdomized trial evidence,3 preoperative use of b-blockers is
associated with reduced rates of perioperative cardiovascu-
lar events after coronary artery bypass grafting (CABG) sur-
gery in observational studies.4-6 However, these studies
have largely examined outcomes in the first few days after
surgical intervention, and whether b-blockers should be
continued at the time of discharge after cardiac surgery
remains a topic of debate.
Although some opinion leaders recommend the use of
b-blockers in all patients after CABG,7 the only randomized
trial that evaluated b-blockers after CABG did not find any
clinical benefits with metoprolol compared with placebo.8
Likewise, a secondary analysis of data from the Project of
Ex-vivo Vein graft Engineering via Transfection IV (PRE-
VENT IV) trial failed to demonstrate any significant associ-
ation between b-blocker use at the time of discharge and the
rate of death or MI in the 2 years after CABG.9 However,
these negative results were based on small numbers (81 car-
diac events in the MACB trial and 147 deaths or MI in PRE-
VENT IV). Although analyses from the Cooperative
Cardiovascular Project did report significantly lower mortal-
ity10 in post-CABG patients who were taking b-blockers at
the time of discharge, it is important to note that all of these
patients underwent CABG after an acute MI. Similarly, al-
though an analysis of elderly Medicare patients reportedery c July 2010
Abbreviations and Acronyms
ACE ¼ angiotensin-converting enzyme
APPROACH ¼ Alberta Provincial Project for
Outcome Assessment in
Coronary Heart Disease
CABG ¼ coronary artery bypass grafting
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Chan et al Perioperative Managementa lower mortality rate (hazard ratio, 0.88; 95% confidence
interval [CI], 0.81–0.97) in the subsequent 4 years in those
who were discharged with b-blockers, these patients were
elderly (average age, 76 years), and more than half had heart
failure.11 Thus these 2 studies could not answer the question
of whether b-blockers should be administered to all patients
after CABG or merely to those with history of recent MI or
heart failure. Although the American College of Cardiology/
American Heart Association guidelines recommend long-
term aspirin and statin therapy in all patients after CABG,
their comments on b-blocker use are limited to encouraging
their use in the immediate perioperative period to reduce the
risk of atrial fibrillation.12
Thus we designed this study to investigate the effect of
b-blocker use after the immediate perioperative period in pa-
tients undergoing nontransplant cardiac surgery on all-cause
mortality using data from the Alberta Provincial Project for
Outcome Assessment in Coronary Heart Disease
(APPROACH).13P
MMATERIALS AND METHODS
Study Cohort
All adult patients undergoing nontransplant cardiac surgery at the Uni-
versity of Alberta Hospital in Edmonton, Alberta, Canada, were prospec-
tively enrolled into APPROACH13 during the study period between
September 2002 and August 2005 (n ¼ 3864). The APPROACH study
has been approved by the University of Alberta Health Research Ethics
Board, and all study participants provided written informed consent before
study entry. We excluded patients who died during the index surgical hos-
pitalization (n ¼ 13) or for whom we did not have data on discharge med-
ications (n ¼ 749). As a result, our cohort consisted of 3102 patients who
underwent nontransplant cardiac surgery, who survived to discharge, and
for whom we had discharge medication data. Of note, baseline demograph-
ics and comorbidities were similar in those patients with or without data on
discharge medications.
Data Collection and Variables
Baseline information on demographic and clinical factors were collected
through the APPROACH Project (in which all diagnoses before index car-
diac catheterization are assigned by cardiologists and all data are double
checked and entered into the database by specially trained cardiac nurses).
Laboratory and medication data were collected at the time of preoperative
CABG assessment, as described previously.14 Discharge medication data
were collected from review of discharge summaries.The Journal of Thoracic and CaExposure
The exposure variable of interest was the use of b-blockers at the time of
discharge after cardiac surgery.
Outcome
Vital status for all APPROACH patients is obtained through linkage to
the registry file of Alberta Health and Wellness, and we obtained mortality
data up to October 31, 2008. In addition, 30-day mortality rates for all pa-
tients undergoing cardiac surgery are collected by specially trained cardiac
nurses from review of medical records.
Statistical Analyses
We compared demographics, clinical characteristics, and medication use
in those patients who were discharged with b-blockers (vs not) by using the
c2 test for dichotomous variables and Student’s t test for continuous vari-
ables. We examined the association between b-blocker prescription at dis-
charge and mortality. Our primary analysis was for 1-year mortality, but
in sensitivity analyses we examined mortality in the first 30 days after dis-
charge, mortality 31 to 365 days after hospital discharge, and long-term
mortality. In addition, we conducted subgroup analyses in which we exam-
ined the association between b-blocker use and outcomes in various
subgroups defined by baseline characteristics.
In those patients who underwent CABG, we used multiple logistic
regression to adjust for those variables that were associated with mortality
after hospital discharge to test whether the associations between discharge
prescription for b-blockers and mortality were robust. We considered for in-
clusion in our multivariate models any factors in Table 1 that were imbal-
anced between arms (at a P< .2), had a prevalence of at least 1%, and
were associated (on bivariate analysis) with 1-year mortality after hospital
discharge or were believed to be important to include based on prior litera-
ture, clinical experience (including year of operation), or both. We selected
the variables for our models using the backward stepwise selection tech-
nique with an entry P value of .25 or less and an exit P value of .05 (see
Table 2 for the results of these multivariate analyses). We examined all
first-order interaction terms, but none achieved a level of significance of
a P value of less than .10. We also conducted a Cox proportional hazards
analysis to examine whether b-blocker use at hospital discharge was asso-
ciated with long-termmortality in patients discharged from the hospital after
adjusting for those covariates that were associated with long-term mortality
in our cohort, as well as other dischargemedications. Finally, as a sensitivity
analysis, we performed a conditional logistic regression analysis on a pro-
pensity-matched subset of patients undergoing CABGmatched on their pre-
dicted probability of receiving a b-blocker (by using the greedy matching
technique after developing predicted probabilities [ie, propensity scores]
for receiving a b-blocker for every patient in the cohort based on baseline
characteristics, including age, sex, comorbidities, and other medications).15
All analyses were conducted with SPSS version 17.0 software (SPSS, Inc,
Chicago, Ill), except for the analysis of long-term mortality, for which SAS
version 9.0 software (SAS Institute, Inc, Cary, NC) was used.RESULTS
Of the 3102 patients in our cohort, 2547 (82%) underwent
CABG (99% on pump). At discharge, 2580 (83%) patients
were prescribed a b-blocker. The imbalances in prognostic
factors generally favored the b-blocker nonusers because
they had a lower burden of comorbidities and were less
likely to be undergoing urgent/emergency CABG (Table
1). In those patients who had their left ventricular ejection
fraction measured, reduced systolic function was more com-
mon in b-blocker users than nonusers (Table 1). Those pa-
tients discharged with b-blockers were more likely to berdiovascular Surgery c Volume 140, Number 1 183
TABLE 1. Characteristics of 3102 patients undergoing nontransplant
cardiac surgery stratified by discharge b-blocker use
b-Blocker
users
(n ¼ 2580)
b-Blocker
nonusers
(n ¼ 522)
P
value
Age, y (mean  SD) 65.2  10.8 65.7  12.6 .41
Male sex 2059 (80) 327 (63) <.001
Metropolitan residence 1584 (61) 315 (60) .65
Procedure <.001
Isolated CABG 1800 (70) 177 (34)
CABG plus other 444 (17) 126 (24)
Other* 336 (13) 219 (42)
Priority .05
Elective 907 (35) 210 (40)
Urgent or emergency 1525 (59) 289 (55)
Unknown 148 (6) 23 (5)
Myocardium at risk, Duke
Jeopardy scorey (mean  SD)
43.0  36.0 43.4  36.0 .85
Left ventricular ejection fraction .003
Normal 1257 (49) 254 (49)
30%–49% 644 (25) 104 (20)
<30% 180 (7) 40 (8)
Not measured 499 (19) 124 (24)
Comorbidities
Prior MI 1037 (40) 136 (26) <.001
Prior CABG 59 (2) 20 (4) .04
Hypertension 1788 (69) 297 (57) <.001
Diabetes mellitus 742 (29) 119 (23) .006
Hyperlipidemia 1954 (76) 283 (54) <.001
Peripheral vascular disease 294 (11) 59 (11) .95
Cerebrovascular disease 210 (8) 60 (12) .01
Chronic kidney disease 88 (3) 41 (8) <.001
Hemodialysis 28 (1) 21 (4) <.001
Heart failure 351 (14) 132 (25) <.001
Smoking history
Current smoker 670 (26) 111 (21) .02
Ever smoked 1098 (43) 192 (37) .02
Chronic obstructive lung disease 311 (12) 105 (20) <.001
Malignancy<5 y 76 (3) 21 (4) .20
Liver/GI disease 129 (5) 34 (7) .16
Creatinine (mean  SD)z 104.6  65.5 119.8  101.1 .04
Other medications (at time of discharge)
Aspirin 2416 (94) 435 (83) <.001
Ticlopidine, clopidogrel, or both 204 (8) 18 (3) <.001
ACE inhibitor 1048 (41) 184 (35) .02
Statin 1939 (75) 236 (45) <.001
Calcium-channel blocker 1 (0.04) 0 (0.00) .65
Bypass data
Duration of controlled cardiac
ischemia, crossclamp time,
min (mean  SD)x
74.3  37.2 94.9  47.8 <.001
All columns report frequencies (percentages) unless otherwise stated. Only 2 patients
were taking angiotensin receptor blockers preoperatively, and thus angiotensin recep-
tor blockers are not included in this table. SD, Standard deviation; CABG, coronary
artery bypass grafting; MI, myocardial infarction; GI, gastrointestinal; ACE,
angiotensin-converting enzyme. *Other operations included aortic valve surgery
(n¼ 185), mitral valve replacement or repair (n¼ 79), operations on 2 or more valves
(n ¼ 66), repairs of atrial or ventricular septal defects (n ¼ 71), aortic root surgery
(n ¼ 28), tricuspid or pulmonary valve surgery (n ¼ 2), and ‘‘unspecified’’
(n¼ 124). yThe Duke Jeopardy score was only calculated for patients undergoing cor-
onary artery bypass grafting. zCreatinine values were unavailable for 1679 patients.
xNote that these mean crossclamp times exclude the 14 b-blocker users and 3 nonusers
who had their coronary artery bypass grafting done off pump.
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Mmale and were more likely to be discharged with aspirin or
other antiplatelet agents, angiotensin-converting enzyme
(ACE) inhibitors, or statins (all highly statistically signifi-
cant, Table 1). Although there was no difference in preoper-
ative Duke Jeopardy score (which approximates the amount
of myocardium at ischemic risk and is predictive of 1-year
mortality in patients undergoing CABG16) between those
discharged with b-blockers and those not, those who were
discharged with b-blockers appeared to have less compli-
cated operations based on the differences in controlled car-
diac ischemia time (74.3 vs 94.9 minutes, P < .001).
Similar differences between b-blocker users and nonusers
were observed when comparisons were restricted to the
2547 patients who underwent CABG (see Table E1).
Over a mean follow-up of 75.2 months (standard devia-
tion, 20.2 months), 10% (259/2580) of those who were dis-
charged with b-blockers and 19% (97/522) of those who
were not prescribed b-blockers at the time of hospital
discharge died (Figure 1). In the first year after surgical
discharge, 2.2% (57/2580) of b-blocker users and 7.3%
(38/522) of nonusers died (compared with 6% [44/736] of
those patients for whom we did not have discharge prescrip-
tion data). Even after excluding the 25 patients who died
within the first 4 weeks of discharge after their cardiac sur-
gery (9/2580 b-blocker users vs 16/522 nonusers; unad-
justed odds ratio [OR], 0.11; 95% CI, 0.05–0.25),
discharge b-blocker users were less likely to die in months
2 to 12 postoperatively (48/2571 b-blocker users vs 22/
506 nonusers; unadjusted OR, 0.42, 95% CI, 0.25–0.70).
Subgroup analyses confirmed that the association be-
tween b-blocker use and lower mortality was consistent
across all examined subgroups, including patients without
a history of MI or heart failure (Figure 2). Of note, although
the associations between b-blocker use and mortality were
nonsignificant for female patients and those who underwent
non-CABG operations, this reflected the low number of pa-
tients in these subgroups rather than any qualitative differ-
ence between subgroups because all statistical tests for
interaction were nonsignificant. Similar consistency of ef-
fect across subgroups was seen in the 2547 patients who un-
derwent CABG operations (Figure 3). Moreover, the
association between b-blocker discharge and lower 1-year
mortality was consistent across study years (from an OR
of 0.32 [95% CI, 0.12–0.84] in those patients undergoing
operations in 2002 to an OR of 0.24 [95% CI, 0.11–0.54]
in those patients undergoing operations in 2005). Discharge
b-blocker use was associated with substantially lower 1-year
mortality rates in the 251 patients who were not discharged
with aspirin (4.9% vs 45%; OR, 0.06; 95% CI, 0.03–0.14),
the 927 patients who were not discharged with a statin
(3.4% vs 15.4%; OR, 0.20; 95% CI, 0.12–0.33), and the
133 patients who were not discharged with aspirin or a statin
(3.1% vs 55.6%; OR, 0.03; 95% CI, 0.01–0.11). Patients
who were discharged with aspirin and a statin had lowerery c July 2010
TABLE 2. Multivariate predictors of mortality in 2547 patients
discharged after CABG surgery
Variable
One-year mortality,
OR (95% CI)
Long-term mortality,*
HR (95% CI)
Age (per year) 1.05 (1.02–1.07) 1.06 (1.05–1.07)
Comorbidities
Chronic kidney
disease
2.34 (1.12–4.90) 1.99 (1.37–2.91)
Heart failure 2.01 (1.14–3.57) 2.03 (1.55–2.66)
Diabetes mellitus 1.66 (1.00–2.77) 1.30 (1.02–1.66)
Medications
b-Blockers 0.54 (0.30–0.97) 0.65 (0.49–0.87)
Aspirin 0.15 (0.08–0.25) 0.39 (0.28–0.53)
Statins 0.46 (0.26–0.79) 0.76 (0.59–0.98)
ACE inhibitors 0.69 (0.40–1.20) 0.69 (0.54–0.89)
CABG, Coronary artery bypass grafting; OR, odds ratio; CI, confidence interval; HR,
hazard ratio; ACE, angiotensin-converting enzyme. *Long-term mortality was defined
as death during the entire duration of follow-up. Year of operation and crossclamp time
were adjusted in both the 1-year mortality model and the long-term mortality model,
although neither was statistically significant in either model. Other covariates that were
significant on bivariate analysis but not after adjustment for the other covariates in the
multivariate model included sex, prior myocardial infarction, prior coronary artery by-
pass grafting, hypertension, hyperlipidemia, cerebrovascular disease, being a smoker,
chronic obstructive lung disease, left ventricular ejection fraction, and priority of sur-
gery (elective vs urgent/emergency). Note that aspirin, statins, angiotensin-converting
enzyme inhibitors, and b-blockers were forced into both models.
0.24
0.31
0.23
0.72
0.20
0.55
0.22
Beta-Blocker Indications
Prior MI
No Prior MI
Heart Failure
Type of Surgery
CABG 
Non-CABG
Male
Female
Death Within 1 Year
0.39
0.29
0.09
0.12
0.23
0.16
0.24
0.42
0.00 0.50 1.00 1.50 2.00Odds Ratio:
Medical History
Hypertension
Diabetes Mellitus
Hyperlipidemia
Cerebrovascular Disease
Chronic Kidney Disease
Present Smoker
Chronic Pulmonary Disease
No Heart Failure
FIGURE2. Association between discharge b-blocker use andmortality af-
ter nontransplant cardiac surgery in subgroups. Subgroup analyses confirm-
ing that the association between b-blocker use and lower mortality is
consistent across all examined subgroups are shown. CABG, Coronary
artery bypass grafting; MI, myocardial infarction.
Chan et al Perioperative Management1-year mortality rates (1.7%), and although discharge
b-blocker use was still associated with lower 1-year mortal-
ity in this subgroup (OR, 0.68), this did not achieve statisti-
cal significance (95% CI, 0.26–1.77) because of the small
number of deaths in this subgroup.
Variables associated with 1-year postoperative mortality
in patients undergoing CABG are outlined in Table 2 (c-sta-
tistic for this model¼ 0.801). After adjusting for these cova-
riates in multivariate analysis, discharge b-blocker useFIGURE 1. Kaplan–Meier curve of survival after hospital discharge. Over
a mean follow-up of 75.2 months (standard deviation, 20.2 months), 10%
(259/2580) of those who were discharged with b-blockers and 19% (97/
522) of those who were not prescribed b-blockers at the time of hospital
discharge died.
The Journal of Thoracic and Caremained significantly associated with a lower risk of
1-year mortality (adjusted OR, 0.54; 95% CI, 0.30–0.97).
Even after excluding the 20 patients undergoing CABG
who died within the first 4 weeks of discharge, the associa-
tion between discharge b-blocker use and lower mortality at
1 year persisted after covariate adjustment (adjusted OR,
0.56; 95% CI, 0.29–1.07), although it fell short of statistical
significance because of the smaller number of deaths in this
analysis. On Cox proportional hazards analysis adjusting for
the covariates in Table 2 and examining survival over
a mean follow-up of over 6 years, the hazard ratio for
long-term mortality associated with b-blocker use at the
time of hospital discharge was 0.65 (95% CI, 0.49–0.87).
In our propensity-matched sensitivity analysis we were
able to match 288 of the 303 b-blocker nonusers after
CABG surgery with 288 b-blocker users with the same0.30
0.16
0.19
0.21
0.81
0.15
Beta-Blocker Indications
Prior MI
No Prior MI
Heart Failure
No Heart Failure
Male
Female
Death Within 1 Year: Patients Undergoing CABG
0.31
0.23
0.05
0.08
0.20
0.14
0.18
0.00 0.50 1.00 1.50 2.00 2.50 3.00Odds Ratio:
Medical History
Hypertension
Diabetes Mellitus
Hyperlipidemia
Cerebrovascular Disease
Chronic Kidney Disease
Present Smoker
Chronic Pulmonary Disease
FIGURE3. Association between discharge b-blocker use andmortality af-
ter coronary artery bypass grafting in subgroups. Subgroup analyses were
limited to the 2547 patients who had coronary artery bypass graft surgery,
confirming that the association between b-blocker use and lower mortality
is consistent across all examined subgroups.CABG, Coronary artery bypass
grafting; MI, myocardial infarction.
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Mpropensity for b-blocker prescription based on the identified
covariates. The model run on this 576 patient subgroup dem-
onstrated a similar association between b-blocker use and
lower 1-year mortality (OR, 0.53) as our primary analysis,
although it did not achieve statistical significance
(P ¼ .16) because of the smaller sample size compared
with the full cohort used in our primary analysis.
Of the 2580 patients discharged with a b-blocker, 641 had
not been taking ab-blocker preoperatively.Of the 522 patients
discharged without a b-blocker prescription, 194 had been
taking a b-blocker preoperatively. The mortality rates in the
194 patients who had their b-blockers stopped after the oper-
ation were 3.6% in the first 30 days after discharge, 9.8% at
1 year, and 22.7% over the mean follow-up of 50.4 months.
DISCUSSION
In summary, we found that those patients who were dis-
charged with b-blockers after cardiac surgery exhibited
a substantially lower rate of death at 1 year, which was con-
sistent across subgroups and robust to multivariate adjust-
ment. The association between discharge b-blocker use
and lower mortality persisted even after excluding deaths
within the first 4 weeks after discharge and even when ex-
tending follow-up to more than 6 years. Importantly, the
lower mortality risk in b-blocker users was seen in all pa-
tients after cardiac surgery, including those without a prior
history of MI or heart failure, and was particularly marked
in patients after CABG and patients who were not dis-
charged with aspirin, statins, or both.
Thus our findings extend the evidence base supporting the
use of discharge b-blockers after cardiac surgery. Although
earlier studies10,11 demonstrated a similar association
between discharge b-blocker use and lower mortality in
patients undergoing CABG with a history of MI or heart
failure, we have demonstrated a positive association
between discharge b-blockers and survival that extends to
all subgroups we considered. In addition, we have addressed
criticisms that this association might simply reflect
physician selection bias in only prescribing b-blockers to
patients with good prognoses by demonstrating that the
association between b-blocker use and lower mortality was
preserved even after excluding those deaths that occurred in
the first 4 weeks after discharge. Presumably, even if
physicians are accurate in predicting which patients are most
likely to do well, this prognostication ability is unlikely to
extend more than a few weeks after hospital discharge. A
potential mechanistic explanation for our findings arises
from a pooled analysis of intravascular ultrasonographic
trials that demonstrated that coronary atherosclerosis
progression rates were significantly reduced in b-blocker
users compared with those seen in patients not receiving
b-blockade, even after multivariate adjustment.17
Our study cohort is similar to other contemporary audits
of cardiac surgery patients in demographics, clinical comor-186 The Journal of Thoracic and Cardiovascular Surgbidities, and outcome rates.18 Furthermore, our discharge
prescribing rates for secondary prevention medications, al-
though higher than those of studies of a decade ago,10 are
similar to more contemporaneous cohorts.19,20 We did not
survey attending surgeons about why they chose to
discharge some of their patients with b-blockers but not
others. In addition to detecting a positive association
between the use of b-blockers and lower mortality rates
after cardiac surgery, our study also demonstrated that the
use of aspirin and statins is strongly associated with lower
postoperative mortality at 1 year. These findings support
previous reports showing that early initiation of aspirin21
or statins22 after cardiac surgery reduces the risk of death.
The Ischemia Management with Accupril post-bypass Graft
via Inhibition of the converting Enzyme (IMAGINE) trial
found that early initiation of ACE inhibitors after CABG
in stable patients without heart failure, diabetes, or prior
MI was associated with early excess angina but a subsequent
trend toward reduced cardiovascular events and death that
did not achieve statistical significance because of the low
event rates in trial participants.23 A recent cohort study
also suggested that use of ACE inhibitors in the immediate
perioperative setting in patients undergoing CABG might
in fact be associated with worsening of outcomes compared
with those seen in patients not taking ACE inhibitors.24 Thus
our finding of a nonsignificant association between ACE in-
hibitor use and 1-year mortality but reduced long-term mor-
tality in users of ACE inhibitors is consistent with both of
these studies and the data from long-term ACE inhibitor tri-
als demonstrating long-term benefits.
Our study has a number of strengths stemming from the
prospective collection of data, including medications, on
all patients (not just the elderly) undergoing nontransplant
cardiac surgery in one tertiary care institution with 100%
follow-up through linkage to electronic mortality records
(thereby minimizing recall or ascertainment bias). However,
there are some limitations.
First, our study is observational in nature. Despite the ad-
justment for known confounders in multivariate analyses,
we can only investigate associations and cannot infer causa-
tion. However, the consistency of the association between
b-blocker use and outcomes in various subgroups and over
various time periods is persuasive. Moreover, it is worth not-
ing that many of the imbalances in Table 1 favor the
b-blocker nonusers, and this in fact strengthens our conclu-
sion because the b-blocker users exhibited lower mortality
rates despite a higher burden of comorbidities at baseline
and a greater proportion of urgent/emergency CABG.
Second, we only have information on medications pre-
scribed at the time of discharge after cardiac surgery and do
not have data on the number of prescriptions actually filled
and subsequent persistence with these prescriptions. How-
ever, data fromanotherCanadian cohort study19 demonstrated
that b-blocker use is relatively stable after CABG discharge,ery c July 2010
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gardless, any nonadherence to b-blockers after discharge in
our study cohort would have biased our study toward the
null, making it more difficult to detect an association between
discharge b-blocker use and 1-year mortality.
Third, we do not have data on the dosage of medications
used and thus could not explore for dose-response effects.
Fourth, we do not have data on MI or ischemia at the time
of the operation or after hospital discharge, and future stud-
ies should investigate the incidence of such events after car-
diac surgery because presumably the benefits of b-blockade
might well be through their anti-ischemic mechanisms, anti-
arrhythmic mechanisms, or both.
Finally, we do not have data on such operative factors as
number and type of bypass grafts, surgical techniques, and
myocardial protection techniques nor any details on the se-
verity of comorbidities in this patient population (although
our findings were maintained even after adjusting for key
objective measures, such as left ventricular ejection fraction
and Duke Jeopardy score).
In conclusion, despite advances in intraoperative tech-
niques and perioperative care that have resulted in improved
short-term outcomes, long-term outcomes after cardiac sur-
gery have not demonstrated the same impressive improve-
ments over the past 2 decades.25 It has been speculated
that this might be due to suboptimal use of secondary pre-
vention therapies after discharge from surgical intervention.
Certainly, patients after cardiac surgery appear to be less
likely to receive statins, b-blockers, and ACE inhibitors
than survivors of acute coronary syndromes,20,25 and our
data suggest that enhanced use of these medications would
improve long-term outcomes after nontransplant cardiac sur-
gery, especially CABG. Thus even in patients without heart
failure or a prior MI, strong consideration should be given to
the prescription of b-blockers after CABG.
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Table E1. Characteristics of 2547 patients undergoing CABG (either
isolated or plus another procedure) stratified by discharge b-blocker
use
b-Blocker
users
(n ¼ 2244)
b-Blocker
nonusers
(n ¼ 303)
P
value
Age, y (mean  SD) 65.7  10.4 68.8  11.0 <.001
Male sex 1845 (82) 228 (75) .003
Metropolitan residence 1375 (61) 186 (61) .97
Procedure <.001
Isolated CABG 1800 (80) 177 (58)
CABG plus other 444 (20) 126 (42)
Priority .89
Elective 736 (33) 101 (33)
Urgent or emergency 1373 (61) 185 (61)
Unknown 135 (6) 17 (6)
Myocardium at risk,
Duke Jeopardy score*
(mean  SD)
43.0  36.0 43.4  36.0 .85
Comorbidities
Prior MI 1013 (45) 118 (40) .04
Prior CABG 56 (3) 15 (5) .02
Hypertension 1610 (72) 203 (67) .09
Diabetes mellitus 707 (32) 86 (28) .27
Hyperlipidemia 1827 (81) 207 (68) <.001
Peripheral vascular disease 252 (11) 43 (14) .13
Cerebrovascular disease 187 (8) 42 (14) .002
Chronic kidney disease 75 (3) 29 (10) <.001
Hemodialysis 24 (1) 16 (5) <.001
Heart failure 270 (12) 72 (24) <.001
Smoking history
Current smoker 601 (27) 74 (24) .38
Ever smoked 993 (44) 124 (41) .27
Chronic pulmonary disease 258 (12) 62 (21) <.001
Malignancy<5 y 63 (3) 14 (5) .08
Liver/GI disease 114 (5) 21 (7) .18
Creatinine (mean  SD)y 104.3  62.7 129.1  116.0 .01
Other medications (at time of discharge)
Aspirin 2128 (95) 254 (84) <.001
Ticlopidine, clopidogrel, or
both
192 (9) 17 (6) .08
ACE inhibitor 911 (41) 114 (38) .32
Statin 1844 (82) 191 (63) <.001
Calcium-channel blocker 1 (0.04) 0 (0.00) .71
Bypass data
Duration of controlled
cardiac ischemia,
crossclamp
time, min (mean  SD)z
70.9  35.0 91.8  48.3 <.001
All columns report frequencies (percentages) unless otherwise stated. Only 2 patients
were taking angiotensin receptor blockers preoperatively, and thus angiotensin recep-
tor blockers are not included in this table. SD, Standard deviation; CABG, coronary
artery bypass grafting; MI, myocardial infarction; GI, gastrointestinal; ACE,
angiotensin-converting enzyme. *Duke Jeopardy scores were only calculated for pa-
tients undergoing coronary artery bypass grafting. yCreatinine values were unavailable
for 1305 patients. zNote that these mean crossclamp times exclude the 14 b-blocker
users and 3 nonusers who had their coronary artery bypass grafting done off pump.
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